Selçuk Ecza Deposu Ticaret ve Sanayi A.S., (SELEC) Fair Value & Analysis
Healthcare · TR · Market cap 132B TRY
Fair value as of: Aug 1, 2026
From 14 valuation models · updated today
Share price +6.5% over the past month.
What matters now
- The price sits above even our optimistic bull case (121.14 TRY). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (12 months)
12‑month range 66.87 TRY – 261.00 TRY · fair‑value band 69.59 TRY – 121.14 TRY · the 213.00 TRY price screens above the 95.36 TRY fair value. As of Aug 1, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Selçuk Ecza Deposu Ticaret ve Sanayi A.S., (SELEC) currently trades at 213.00 TRY, while our model-based Fair Value estimate is 95.36 TRY, implying the stock looks roughly 55.2% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Selçuk Ecza Deposu Ticaret ve Sanayi A.S., generated revenue of 175B TRY at a net margin of 0.7%. Revenue grew 5.8% year over year. It earns a return on equity of 3.8%. Net debt stands at 4.8B TRY. Fundamentals as of Aug 1, 2026
Our scenario range runs from 69.59 TRY (bear case) to 121.14 TRY (bull case); at 213.00 TRY, the current price sits above that range. The share trades about 23% below its 52-week high and 223% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -55%, SELEC screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Selçuk Ecza Deposu Ticaret ve Sanayi A.S., together with its subsidiary, operates as a pharmacy depot in Turkey. In addition, the company is involved in operation of pharmaceutical warehouses; and distributes cosmetics, personal care, infant food, vitamins, medical, and other products. The company was founded in 1958 and is based in Istanbul, Turkey.
Full company description
Selçuk Ecza Deposu Ticaret ve Sanayi A.S., together with its subsidiary, operates as a pharmacy depot in Turkey. In addition, the company is involved in operation of pharmaceutical warehouses; and distributes cosmetics, personal care, infant food, vitamins, medical, and other products. The company was founded in 1958 and is based in Istanbul, Turkey. Selçuk Ecza Deposu Ticaret ve Sanayi A.S. is a subsidiary of Selçuk Ecza Holding A.S.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Selçuk Ecza Deposu Ticaret ve Sanayi A.S., reported revenue of 172B TRY in FY2025 versus 26.2B TRY in FY2021, a compound +60.0%/yr. Reported net income was −380M TRY in FY2025.
Is SELEC fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$958.36 | R$188.90 | -80% |
| Cencora, Inc COR | $271.28 | $175.74 | -35% |
| Cardinal Health, Inc CAH | $201.74 | $92.07 | -54% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Henry Schein, Inc HSIC | $76.30 | $53.31 | -30% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALNF | $115.00 | $84.59 | -26% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥20.81 | ¥30.70 | +48% |
| Medipal Holdings MEPDF | $18.35 | $29.88 | +63% |
Compare Selçuk Ecza Deposu Ticaret ve Sanayi A.S., with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Selçuk Ecza Deposu Ticaret ve Sanayi A.S., (SELEC) overvalued or undervalued?
What is the fair value of SELEC?
What is the quality score of SELEC?
What is the revenue of Selçuk Ecza Deposu Ticaret ve Sanayi A.S., (SELEC)?
What is the net profit margin of SELEC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Selçuk Ecza Deposu Ticaret ve Sanayi A.S., and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.